MA52873A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies

Info

Publication number
MA52873A
MA52873A MA052873A MA52873A MA52873A MA 52873 A MA52873 A MA 52873A MA 052873 A MA052873 A MA 052873A MA 52873 A MA52873 A MA 52873A MA 52873 A MA52873 A MA 52873A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
pharmaceutical compositions
new compounds
associated pharmaceutical
Prior art date
Application number
MA052873A
Other languages
English (en)
Inventor
David Amantini
Reginald Christophe Xavier Brys
Denis Bucher
Vos Steve Irma Joel De
Nicolas Desroy
Agnès Marie Joncour
Christophe Peixoto
Taoues Temal-Laib
Amynata Tirera
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1809836.8A external-priority patent/GB201809836D0/en
Priority claimed from GBGB1817344.3A external-priority patent/GB201817344D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA52873A publication Critical patent/MA52873A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA052873A 2018-06-15 2019-05-29 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies MA52873A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1809836.8A GB201809836D0 (en) 2018-06-15 2018-06-15 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GBGB1817344.3A GB201817344D0 (en) 2018-10-25 2018-10-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MA52873A true MA52873A (fr) 2021-04-21

Family

ID=66810768

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052873A MA52873A (fr) 2018-06-15 2019-05-29 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies

Country Status (16)

Country Link
US (1) US12264156B2 (fr)
EP (1) EP3806853B1 (fr)
JP (1) JP7399116B2 (fr)
KR (1) KR102758615B1 (fr)
CN (2) CN118359612A (fr)
AU (1) AU2019286162B2 (fr)
BR (1) BR112020025202A2 (fr)
CA (1) CA3103304A1 (fr)
CO (1) CO2021000159A2 (fr)
IL (1) IL279397B2 (fr)
MA (1) MA52873A (fr)
MX (1) MX2020013275A (fr)
PH (1) PH12020552160A1 (fr)
SG (1) SG11202012458RA (fr)
TW (1) TW202015677A (fr)
WO (1) WO2019238424A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
GB201907558D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
US10702525B1 (en) * 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
BR112023001952A2 (pt) * 2020-08-05 2023-02-28 Massachusetts Gen Hospital Inibidores de quinase induzíveis por sal
WO2022174253A1 (fr) * 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Antagonistes de hpk1 et leurs utilisations
WO2022213062A1 (fr) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Antagonistes de hpk1 et leurs utilisations
CN115197208A (zh) * 2021-04-01 2022-10-18 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
AU2023283393A1 (en) * 2022-06-10 2025-01-02 Interline Therapeutics, Inc. Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024104441A1 (fr) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Inhibiteurs de kinases inductibles par sel (sik) et leurs procédés d'utilisation
IL324835A (en) 2023-05-24 2026-01-01 Mitsubishi Tanabe Pharma Corp Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same
AU2024352869A1 (en) * 2023-09-26 2026-04-09 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025232877A1 (fr) * 2024-05-10 2025-11-13 Insilico Medicine Ip Limited Inhibiteurs de kinases inductibles au sel (sik)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2376490T3 (da) 2008-12-04 2013-04-15 Proximagen Ltd Imidazopyridinforbindelser
JP6267863B2 (ja) * 2009-10-16 2018-01-24 メリンタ セラピューティクス，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
CN109641906B (zh) * 2015-06-24 2021-10-01 百时美施贵宝公司 杂芳基取代的氨基吡啶化合物
CN106496222A (zh) * 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
BR112023001952A2 (pt) 2020-08-05 2023-02-28 Massachusetts Gen Hospital Inibidores de quinase induzíveis por sal
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024141444A1 (fr) 2022-12-27 2024-07-04 F. Hoffmann-La Roche Ag Nouveaux dérivés de benzimidazole

Also Published As

Publication number Publication date
IL279397B1 (en) 2023-11-01
CN112292129B (zh) 2024-04-19
CA3103304A1 (fr) 2019-12-19
CN112292129A (zh) 2021-01-29
IL279397A (en) 2021-01-31
JP2021527106A (ja) 2021-10-11
CO2021000159A2 (es) 2021-01-18
EP3806853B1 (fr) 2026-03-18
MX2020013275A (es) 2021-02-18
NZ771898A (en) 2025-10-31
TW202015677A (zh) 2020-05-01
WO2019238424A1 (fr) 2019-12-19
AU2019286162B2 (en) 2025-02-13
SG11202012458RA (en) 2021-01-28
KR20210022055A (ko) 2021-03-02
IL279397B2 (en) 2024-03-01
US20220402911A1 (en) 2022-12-22
EP3806853A1 (fr) 2021-04-21
CN118359612A (zh) 2024-07-19
US12264156B2 (en) 2025-04-01
AU2019286162A1 (en) 2021-02-04
JP7399116B2 (ja) 2023-12-15
KR102758615B1 (ko) 2025-01-22
BR112020025202A2 (pt) 2021-03-09
PH12020552160A1 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA55325A (fr) Composés pour le traitement de maladies pd-l1
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3716767A4 (fr) Méthodes et compositions pour le traitement de maladies rares
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
SG11202012458RA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3883554A4 (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP3655403A4 (fr) Composés affectant la production de pigments et leur utilisation pour le traitement de maladies bactériennes
EP3621593A4 (fr) Compositions pharmaceutiques et méthodes de traitement de maladies cardiovasculaires